- Home
- SOAR vs CLDI Comparison
SOAR vs CLDI Comparison
Compare SOAR & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOAR | CLDI |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 9.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOAR | CLDI |
|---|---|---|
| Price | $1.23 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 174.7K | 88.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $1.10 |
| 52 Week High | $7.45 | $24.12 |
Technical Indicators
Market Signals| Indicator | SOAR | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 49.93 |
| Support Level | $1.19 | $1.41 |
| Resistance Level | $1.35 | $1.54 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 36.84 | 72.73 |
Price Performance
Historical ComparisonAbout SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.